Online inquiry

IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4324MR)

This product GTTS-WQ4324MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets C1S gene. The antibody can be applied in Cold agglutinin disease (CAD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001346850.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 716
UniProt ID P09871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ4324MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6661MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ4954MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ10836MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ9446MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IPH4102
GTTS-WQ4341MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIW-8405
GTTS-WQ7087MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ9083MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMCgp100
GTTS-WQ1930MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGN 150998
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW